LONDON, July 21, 2021 /PRNewswire/ -- Clarivate Plc
(NYSE: CLVT), a global leader in providing trusted information and
insights to accelerate the pace of innovation, today announced the
launch of the Cortellis Supply Chain Network™, a part of the
Cortellis suite of life science intelligence solutions. The
solution supports generics companies, Active Pharmaceutical
Ingredients (API) manufacturers, fine chemical manufacturers,
excipient manufacturers, raw materials suppliers, and biopharma in
their pursuit to maintain a steady supply chain -- ultimately
making therapies easily accessible to all patients. The Cortellis
Supply Chain Network can connect more than 70K+ companies – buyers
and sellers – with more data added by the expert research team and
directly by users every day.
Vulnerabilities in pharma supply chains have been an
increasingly important focus in the industry with the coronavirus
pandemic further exposing shortcomings within the global supply
chain.1 These vulnerabilities have led key industry
players, from manufacturers to government bodies, to proactively
monitor and mitigate supply risk. Identifying new suppliers and
contacts within generics and biopharma companies to provide APIs or
excipients for drug manufacturing can often be challenging for
procurement, sourcing teams and manufacturers. Buyers find it
difficult to keep track of new manufacturers and existing
manufacturers' expansion into new capabilities – and sellers find
it challenging to stand out from the competition.
Cortellis Supply Chain Network provides buyers and sellers with
a secure marketplace that allows them to identify potential
partners, connect with the right point of contact, and efficiently
manage all steps, from quotation to finalizing the deal. With an
increased demand for more accessible therapies, the network will
enable industry players to build robust supply chains and identify
alternate sources during unprecedented times.
Identifying alternate API sources and other critical ingredients
to prevent manufacturing delays caused by unexpected events, can
help build a resilient supply chain. Cortellis Supply Chain Network
provides access to continuously updated manufacturing data, saving
users time in confidently assessing potential partners.
High-quality product data is paired with primary research on API
manufacturers to verify their pipeline and manufacturing
capabilities. Users can monitor and manage supply risk with
insights on the latest inspections, warning letters, GMP
Certificates, supply issues and more. In addition, it provides
users with personalized updates, documentation, and alerts to
support overall supply transparency in the industry.
Keith Collier SVP Product -
Science, Clarivate, said: "The COVID-19 pandemic put a spotlight on
drug supply chains across the globe, especially for critical and
essential medicines. Although the generics industry has long
identified an over-reliance on China and India to supply APIs and key starting
materials, the pandemic highlighted a critical need for greater
transparency and reliable supply chains. As an organization
committed to supporting customers across the entire drug, device
and medical technology lifecycles to drive clinical and commercial
success, Clarivate developed the Cortellis Supply Chain Network,
which aims to open communication channels between manufacturers,
provide insights on supply capabilities or vulnerabilities and
facilitate deal-making."
The Cortellis Supply Chain Network is powered by the Clarivate
Research Intelligence Cloud™ -- allowing more comprehensive
research and analysis during market assessment activities. The
Cortellis Supply Chain Network is just one of the many investments
Clarivate has made and will continue to make – expanding and
enhancing its suite of life science intelligence solutions in
response to customer needs.
To learn more, visit the Cortellis Supply Chain Network
here.
About Clarivate
Clarivate™ is a global leader in providing solutions to
accelerate the lifecycle of innovation. Our bold mission is to help
customers solve some of the world's most complex problems by
providing actionable information and insights that reduce the time
from new ideas to life-changing inventions in the areas of science
and intellectual property. We help customers discover, protect and
commercialize their inventions using our trusted subscription and
technology-based solutions coupled with deep domain expertise. For
more information, please visit clarivate.com.
Media Contact
Catherine
Daniel
media.enquiries@clarivate.com
1 Fitzhugh, Michael. "Experts seek path to building a
more resilient drug supply chain." BioWorld,
https://www.bioworld.com/articles/506084-experts-seek-path-to-building-a-more-resilient-drug-supply-chain?v=preview.
April 19, 2021.
Logo -
https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg